Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015, Article ID 352478, 10 pages
http://dx.doi.org/10.1155/2015/352478
Review Article

Prognostic Value of FOXM1 in Patients with Malignant Solid Tumor: A Meta-Analysis and System Review

1Institute of Pathology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
2Department of Pediatrics, The Second Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou 310009, China

Received 17 March 2015; Accepted 23 June 2015

Academic Editor: Dinesh Kumbhare

Copyright © 2015 Jun Dai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA: Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. M. M. Kirstein, A. Lange, A. Prenzler, M. P. M. Anns, S. Kubicka, and A. Vogel, “Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data,” Oncologist, vol. 19, no. 11, pp. 1156–1168, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. M. S. Anscher, “Targeting the TGF-β1 pathway to prevent normal tissue injury after cancer therapy,” The Oncologist, vol. 15, no. 4, pp. 350–359, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Pilarsky, M. Wenzig, T. Specht, H. D. Saeger, and R. Grützmann, “Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data,” Neoplasia, vol. 6, no. 6, pp. 744–750, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. Z. Wang, A. Ahmad, Y. Li, S. Banerjee, D. Kong, and F. H. Sarkar, “Forkhead box M1 transcription factor: a novel target for cancer therapy,” Cancer Treatment Reviews, vol. 36, no. 2, pp. 151–156, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Wierstra and J. Alves, “FOXM1, a typical proliferation-associated transcription factor,” Biological Chemistry, vol. 388, no. 12, pp. 1257–1274, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Laoukili, M. R. H. Kooistra, A. Brás et al., “FoxM1 is required for execution of the mitotic programme and chromosome stability,” Nature Cell Biology, vol. 7, no. 2, pp. 126–136, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Laoukili, M. Stahl, and R. H. Medema, “FoxM1: at the crossroads of ageing and cancer,” Biochimica et Biophysica Acta, vol. 1775, no. 1, pp. 92–102, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Raychaudhuri and H. J. Park, “FoxM1: a master regulator of tumor metastasis,” Cancer Research, vol. 71, no. 13, pp. 4329–4333, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Gemenetzidis, A. Bose, A. M. Riaz et al., “FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation,” PLoS ONE, vol. 4, no. 3, Article ID e4849, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. D. A. Sanders, C. S. Ross-Innes, D. Beraldi, J. S. Carroll, and S. Balasubramanian, “Genome-wide mapping of FOXM1 binding reveals co-binding with estrogen receptor alpha in breast cancer cells,” Genome Biology, vol. 14, article R6, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. S.-Y. He, H.-W. Shen, L. Xu et al., “FOXM1 promotes tumor cell invasion and correlates with poor prognosis in early-stage cervical cancer,” Gynecologic Oncology, vol. 127, no. 3, pp. 601–610, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Xia, W. Huang, D. Tian et al., “Upregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma,” Journal of Hepatology, vol. 57, no. 3, pp. 600–612, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Okada, Y. Fujiwara, T. Takahashi et al., “Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer,” Annals of Surgical Oncology, vol. 20, no. 3, pp. 1035–1043, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Xu, D. Jia, W. Chen et al., “FoxM1 is associated with poor prognosis of non-small cell lung cancer patients through promoting tumor metastasis,” PLoS ONE, vol. 8, no. 3, Article ID e59412, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Bektas, A. ten Haaf, J. Veeck et al., “Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer,” BMC Cancer, vol. 8, article 42, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. M. K. B. Parmar, V. Torri, and L. Stewart, “Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints,” Statistics in Medicine, vol. 17, no. 24, pp. 2815–2834, 1998. View at Google Scholar · View at Scopus
  18. J. F. Tierney, L. A. Stewart, D. Ghersi, S. Burdett, and M. R. Sydes, “Practical methods for incorporating summary time-to-event data into meta-analysis,” Trials, vol. 8, article 16, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” British Medical Journal, vol. 327, no. 7414, pp. 557–560, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Geller, L. Freedman, Y. J. Lee, and R. DerSimonian, “Conference on meta-analysis in the design and monitoring of clinical trials,” Statistics in Medicine, vol. 18, no. 6, pp. 753–754, 1999. View at Google Scholar
  21. A. Bergamaschi, Z. Madak-Erdogan, Y. Kim, Y. Choi, H. Lu, and B. S. Katzenellenbogen, “The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells,” Breast Cancer Research, vol. 16, no. 5, article 436, 2014. View at Publisher · View at Google Scholar
  22. S. G. Ahn, H. M. Lee, H. W. Lee et al., “Prognostic discrimination using a 70-gene signature among patients with estrogen receptor-positive breast cancer and an intermediate 21-gene recurrence score,” International Journal of Molecular Sciences, vol. 14, no. 12, pp. 23685–23699, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Li, P. Wei, Z. Peng et al., “The critical role of dysregulated FOXM1-PLAUR signaling in human colon cancer progression and metastasis,” Clinical Cancer Research, vol. 19, no. 1, pp. 62–72, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. X.-Y. Chu, Z.-M. Zhu, L.-B. Chen et al., “FOXM1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer,” Acta Histochemica, vol. 114, no. 8, pp. 755–762, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Takata, S. Takiguchi, K. Okada et al., “Clinicopathological and prognostic significance of FOXM1 expression in esophageal squamous cell carcinoma,” Anticancer Research, vol. 34, no. 5, pp. 2427–2432, 2014. View at Google Scholar · View at Scopus
  26. R. Wang, Y. Song, X. Xu, Q. Wu, and C. Liu, “The expression of Nek7, FoxM1, and Plk1 in gallbladder cancer and their relationships to clinicopathologic features and survival,” Clinical and Translational Oncology, vol. 15, no. 8, pp. 626–632, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. C.-J. Hu, B. Wang, B. Tang et al., “The FOXM1-induced resistance to oxaliplatin is partially mediated by its novel target gene Mcl-1 in gastric cancer cells,” Biochimica et Biophysica Acta—Gene Regulatory Mechanisms, vol. 1849, no. 3, pp. 290–299, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. X. Li, W. Qiu, B. Liu et al., “Forkhead box transcription factor 1 expression in gastric cancer: FOXM1 is a poor prognostic factor and mediates resistance to docetaxel,” Journal of Translational Medicine, vol. 11, article 204, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Zhang, X. Wu, L. Yang et al., “FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51,” Clinical Cancer Research, vol. 18, no. 21, pp. 5961–5971, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Sun, M. Teng, J. Liu et al., “FOXM1 expression predicts the prognosis in hepatocellular carcinoma patients after orthotopic liver transplantation combined with the Milan criteria,” Cancer Letters, vol. 306, no. 2, pp. 214–222, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. H.-C. Sun, M. Li, J.-L. Lu et al., “Overexpression of Forkhead box M1 protein associates with aggressive tumor features and poor prognosis of hepatocellular carcinoma,” Oncology Reports, vol. 25, no. 6, pp. 1533–1539, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. F.-D. Meng, J.-C. Wei, K. Qu et al., “FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 21, no. 1, pp. 196–213, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. L.-Z. Jiang, P. Wang, B. Deng et al., “Overexpression of Forkhead Box M1 transcription factor and nuclear factor-κB in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis,” Human Pathology, vol. 42, no. 8, pp. 1185–1193, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. N. Xu, S.-D. Wu, H. Wang, Q. Wang, and C.-X. Bai, “Involvement of foxm1 in non-small cell lung cancer recurrence,” Asian Pacific Journal of Cancer Prevention, vol. 13, no. 9, pp. 4739–4743, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Chen, Y. Cheng, Y. Wang, T. Wu, C. Chen, and H. Lee, “Up-regulation of FOXM1 by E6 oncoprotein through the MZF1/NKX2-1 axis is required for human papillomavirus-associated tumorigenesis,” Neoplasia, vol. 16, no. 11, pp. 961–971, 2014. View at Publisher · View at Google Scholar
  36. D. K. Yang, C. H. Son, S. K. Lee, P. J. Choi, K. E. Lee, and M. S. Roh, “Forkhead box M1 expression in pulmonary squamous cell carcinoma: correlation with clinicopathologic features and its prognostic significance,” Human Pathology, vol. 40, no. 4, pp. 464–470, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. F.-F. Kong, Z.-Q. Qu, H.-H. Yuan et al., “Overexpression of FOXM1 is associated with EMT and is a predictor of poor prognosis in non-small cell lung cancer,” Oncology Reports, vol. 31, no. 6, pp. 2660–2668, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Wang, L. Wen, S.-H. Zhao, Z.-H. Ai, J.-Z. Guo, and W.-C. Liu, “FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients,” Lung Cancer, vol. 79, no. 2, pp. 173–179, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. Y.-Q. Liu, R.-H. Guo, L.-K. Liu et al., “Correlation between expression of forkhead box M1 (FOXM1) and clinicopathological features and prognosis in patients with non-small cell lung cancer (NSCLC),” Zhonghua Zhong Liu Za Zhi, vol. 33, no. 6, pp. 426–430, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Yu, H. Deshmukh, J. E. Payton et al., “Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor,” Clinical Cancer Research, vol. 17, no. 7, pp. 1924–1934, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Priller, J. Pöschl, L. Abrão et al., “Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients,” Clinical Cancer Research, vol. 17, no. 21, pp. 6791–6801, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. N. Wen, Y. Wang, L. Wen et al., “Overexpression of FOXM1 predicts poor prognosis and promotes cancer cell proliferation, migration and invasion in epithelial ovarian cancer,” Journal of Translational Medicine, vol. 12, article 134, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. F. Zhao, M. K. Y. Siu, L. Jiang et al., “Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance,” PLoS ONE, vol. 9, no. 11, Article ID e113478, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. W.-T. Chiu, Y.-F. Huang, H.-Y. Tsai et al., “FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells,” Oncotarget, vol. 6, no. 4, pp. 2349–2365, 2015. View at Google Scholar · View at Scopus
  45. Z. Ning, A. Wang, J. Liang et al., “USP22 promotes the G1/S phase transition by upregulating FoxM1 expression via β-catenin nuclear localization and is associated with poor prognosis in stage II pancreatic ductal adenocarcinoma,” International Journal of Oncology, vol. 45, no. 4, pp. 1594–1608, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. J.-T. Xia, H. Wang, L.-J. Liang et al., “Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma,” Pancreas, vol. 41, no. 4, pp. 629–635, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. L. Li, Z. Li, X. Kong et al., “Down-regulation of MicroRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells,” Gastroenterology, vol. 147, no. 2, pp. 485–497, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. Y.-J. Xue, R.-H. Xiao, D.-Z. Long et al., “Overexpression of FoxM1 is associated with tumor progression in patients with clear cell renal cell carcinoma,” Journal of Translational Medicine, vol. 10, no. 1, article 200, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. X.-R. Wu, Y.-H. Chen, D.-M. Liu et al., “Increased expression of forkhead box M1 protein is associated with poor prognosis in clear cell renal cell carcinoma,” Medical Oncology, vol. 30, no. 1, article 346, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Ye, T. F. Kelly, U. Samadani et al., “Hepatocyte nuclear factor 3/fork head homolog 11 is expressed in proliferating epithelial and mesenchymal cells of embryonic and adult tissues,” Molecular and Cellular Biology, vol. 17, no. 3, pp. 1626–1641, 1997. View at Google Scholar · View at Scopus
  51. W. Korver, J. Roose, K. Heinen et al., “The human TRIDENT/HFH-11/FKHL16 gene: structure, localization, and promoter characterization,” Genomics, vol. 46, no. 3, pp. 435–442, 1997. View at Publisher · View at Google Scholar · View at Scopus
  52. I.-M. Kim, T. Ackerson, S. Ramakrishna et al., “The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer,” Cancer Research, vol. 66, no. 4, pp. 2153–2161, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. Y. Yoshida, I.-C. Wang, H. M. Yoder, N. O. Davidson, and R. H. Costa, “The forkhead box M1 transcription factor contributes to the development and growth of mouse colorectal cancer,” Gastroenterology, vol. 132, no. 4, pp. 1420–1431, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Liu, B. Dai, S.-H. Kang et al., “FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells,” Cancer Research, vol. 66, no. 7, pp. 3593–3602, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. V. Petrovic, R. H. Costa, L. F. Lau, P. Raychaudhuri, and A. L. Tyner, “FoxM1 regulates growth factor-induced expression of kinase-interacting stathmin (KIS) to promote cell cycle progression,” Journal of Biological Chemistry, vol. 283, no. 1, pp. 453–460, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. H. J. Park, R. H. Costa, L. F. Lau, A. L. Tyner, and P. Raychaudhuri, “Anaphase-promoting complex/cyclosome-Cdh1-mediated proteolysis of the forkhead box M1 transcription factor is critical for regulated entry into S phase,” Molecular and Cellular Biology, vol. 28, no. 17, pp. 5162–5171, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. C. G. Havens, A. Ho, N. Yoshioka, and S. F. Dowdy, “Regulation of late G1/S phase transition and APCCdh1 by reactive oxygen species,” Molecular and Cellular Biology, vol. 26, no. 12, pp. 4701–4711, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. R. Y. M. Ma, T. H. K. Tong, A. M. S. Cheung, A. C. C. Tsang, W. Y. Leung, and K.-M. Yao, “Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1c,” Journal of Cell Science, vol. 118, no. 4, pp. 795–806, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. J. Zeng, L. Wang, Q. Li et al., “FoxM1 is up-regulated in gastric cancer and its inhibition leads to cellular senescence, partially dependent on p27kip1,” Journal of Pathology, vol. 218, no. 4, pp. 419–427, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. I. Wierstra and J. Alves, “FOXM1c transactivates the human c-myc promoter directly via the two TATA boxes P1 and P2,” FEBS Journal, vol. 273, no. 20, pp. 4645–4667, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. Y. Tan, P. Raychaudhuri, and R. H. Costa, “Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes,” Molecular and Cellular Biology, vol. 27, no. 3, pp. 1007–1016, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. S. K. Li, D. K. Smith, W. Y. Leung et al., “FoxM1c counteracts oxidative stress-induced senescence and stimulates Bmi-1 expression,” The Journal of Biological Chemistry, vol. 283, no. 24, pp. 16545–16553, 2008. View at Publisher · View at Google Scholar
  63. B. Bao, Z. Wang, S. Ali et al., “Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells,” Journal of Cellular Biochemistry, vol. 112, no. 9, pp. 2296–2306, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. J. Li, Y. Wang, J. Luo et al., “miR-134 inhibits epithelial to mesenchymal transition by targeting FOXM1 in non-small cell lung cancer cells,” FEBS Letters, vol. 586, no. 20, pp. 3761–3765, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. X. Wang, D. Bhattacharyya, M. B. Dennewitz et al., “Rapid hepatocyte nuclear translocation of the Forkhead Box M1B (FoxM1B) transcription factor caused a transient increase in size of regenerating transgenic hepatocytes,” Gene Expression, vol. 11, no. 3-4, pp. 149–162, 2003. View at Publisher · View at Google Scholar · View at Scopus
  66. B. Dai, S.-H. Kang, W. Gong et al., “Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells,” Oncogene, vol. 26, no. 42, pp. 6212–6219, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. A. Ahmad, Z. Wang, D. Kong et al., “FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors,” Breast Cancer Research and Treatment, vol. 122, no. 2, pp. 337–346, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. Y. Zhang, N. Zhang, B. Dai et al., “FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells,” Cancer Research, vol. 68, no. 21, pp. 8733–8742, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. Q. Li, N. Zhang, Z. Jia et al., “Critical role and regulation of transcription factor foxm1 in human gastric cancer angiogenesis and progression,” Cancer Research, vol. 69, no. 8, pp. 3501–3509, 2009. View at Publisher · View at Google Scholar · View at Scopus